|

HER2,trastuzumab deruxtecan± pertuzumab Clinical Trials

1 actively recruiting trial

Also known as: Cohort9(HER2-positive, DS-8201 ± pertuzumab)

Pipeline

Phase 2: 1

Top Sponsors

  • Peking Union Medical College1

Indications

  • Precision Therapy1
  • Salivary Gland Carcinoma1
  • Cancer1

Other1 trial

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.